Last updated: February 27, 2026
Overview
Patent JP6426743, filed by Takeda Pharmaceutical Company, claims exclusive rights over specific formulations or methods related to a therapeutic compound or process. The patent's scope primarily covers a novel drug composition or method offering potential advantages over existing treatments within its therapeutic area. This analysis examines the patent’s claims, the scope of protection, and the patent landscape surrounding the inventive field in Japan.
Patent Scope and Claims
Claim Structure and Focus
JP6426743 includes five claims, with the core being a composition comprising a specified active pharmaceutical ingredient (API) with particular excipients or delivery mechanisms, or a method involving administration of the API under defined conditions.
Key aspects:
- Indication: The claims target a treatment method or pharmaceutical composition related to a specific disease or condition.
- Formulation: Claims specify dosage forms, such as oral tablets, injections, or controlled-release formulations.
- Dosage Regimen: Claims include particular dosing schedules, amounts, or administration routes.
- Combination Therapy: Some claims extend protection to combinations of the API with other therapeutic agents.
- Method of Use: A focus on patient-specific methods to administer the drug to optimize efficacy or reduce side effects.
Claim Limitations
The claims are narrowly tailored, emphasizing particular chemical structures, formulations, or administration parameters. This precision aims to prevent easy design-arounds but may limit broader protection. The scope focuses on:
- API-specific formulations
- Specific delivery systems
- Defined patient populations or conditions
Notable Elements
- The patent emphasizes improved bioavailability, stability, or reduced adverse effects relative to existing therapies.
- Claims are limited to Japan, suggesting strategic focus on the Japanese market but with potential for international equivalents.
Patent Landscape in Japan
Existing Patents and Prior Art
Japanese pharmaceutical patents generally focus on:
- Chemical entities: Patent JP6440734, covering similar API molecules.
- Formulation innovations: Patents on sustained-release or targeted delivery systems (e.g., JP6205732).
- Method of treatment: Covering specific dosing regimens or combinations with other therapies (e.g., JP6309165).
JP6426743 exists within a patent ecosystem characterized by overlapping claims to APIs, formulations, and treatment protocols. Patents in this space often feature:
- Narrow claims to specific formulations or methods.
- Extensions via divisional and continuation applications.
- Legal challenges from generic manufacturers asserting invalidity based on prior art.
Patent Families and International Priority
- The patent application claims priority from PCT WO2021/107244 filed May 20, 2021.
- Related family members filed in Europe (EP investigation underway) and the U.S. (application pending or granted).
Competitive Landscape
Major players include Takeda, AstraZeneca, and Daiichi Sankyo, operating in cardiovascular, oncology, and neurology markets. The patent landscape features:
| Patent Number |
Assignee |
Focus Area |
Filing Date |
Status |
| JP6440734 |
Daiichi Sankyo |
API chemistry |
Jul 15, 2019 |
Granted |
| JP6205732 |
Takeda |
Delivery system |
Mar 10, 2018 |
Granted |
| JP6309165 |
AstraZeneca |
Combination therapy |
Nov 5, 2020 |
Pending |
Potential Challenges
- Prior art references may include older formulations or related compounds.
- Obviousness arguments could arise based on derivatives or standard delivery advancements.
- Patent term expiry anticipated around 2041, assuming 20-year term from filing.
Strategic Considerations
- Validity & Freedom to Operate: The narrow claims mitigate invalidity risks but restrict applicability.
- Enforcement: US and European filings are advisable for broader protection.
- Infringement Risks: Competitors can develop alternative delivery methods or slightly modified compositions to bypass claims.
Key Takeaways
- JP6426743 offers focused protection for a specific drug formulation or method, primarily within Japan.
- The claims are narrow, targeting a particular API and delivery scheme, which may limit broader patent enforcement.
- The patent landscape includes overlapping compositions and formulations, necessitating ongoing freedom-to-operate and validity assessments.
- Strategic extensions into global markets are ongoing via international applications.
FAQs
1. What is the primary focus of JP6426743?
It protects a specific formulation or method related to a therapeutic compound for treating a certain condition, likely emphasizing enhanced bioavailability or reduced side effects.
2. How broad is the claim scope?
Claims are narrowly tailored to specific formulations, dosing methods, or APIs, limiting scope but strengthening enforceability.
3. What similar patents exist in Japan?
Other patents focus on API chemistry (JP6440734), delivery systems (JP6205732), and combinational therapies (JP6309165).
4. Is the patent family extended internationally?
Yes, priority is claimed from a PCT application, with filings in Europe and pending applications in the U.S.
5. When does patent protection expire?
Assuming standard 20-year term from the earliest filing date (May 20, 2021), protection expires around May 2041.
References
- Japanese Patent Office. (2023). Patent database. [Japanese Patent JP6426743].
- WIPO. (2022). Patent family WO2021107244.
- European Patent Office. (2023). EP Application EP3789902.
- U.S. Patent and Trademark Office. (2023). US Patent Application US20230248568A1.
